Company Overview - Catalyst Pharmaceuticals is a U.S.-based biotechnology company focused on developing and commercializing therapies for rare neuromuscular and neurological diseases [6] - The company has a market capitalization of $2.86 billion, with a revenue of $578.20 million and a net income of $217.56 million for the trailing twelve months (TTM) [4] - Catalyst's stock has experienced a 1-year price change of 11.74% as of December 31, 2025 [4] Recent Transaction - Jeffrey Del Carmen, Chief Commercial Officer, exercised and sold 10,983 shares of common stock on November 26, 2025, for approximately $256,200 [1][2] - This transaction involved converting stock options into cash proceeds, significantly reducing Del Carmen's direct equity holdings by approximately 73.49%, leaving him with 3,962 shares post-transaction [7] - The transaction value was based on a weighted average purchase price of $23.33 per share [2] Financial Performance - Catalyst Pharmaceuticals reported strong third-quarter results with revenues of $148.4 million, reflecting a year-over-year increase of 17.4% [10] - The company raised its full-year 2025 revenue guidance, indicating consistent profitable growth [10] - At the time of the sale, Catalyst's stock was trading between $19.05 and $26.58, with analysts raising price targets to a consensus estimate of around $34 per share [11] Product Portfolio - Key products include Firdapse for Lambert-Eaton myasthenic syndrome (LEMS) and Ruzurgi for pediatric LEMS, with ongoing pipeline development targeting additional rare neuromuscular and neurological indications [8] - The company operates a commercial-stage biopharmaceutical model, generating revenue primarily from the sale of approved therapies for rare diseases in the United States [8]